A Look at Twist Bioscience’s Valuation After Management Highlights Profit Milestones and Growth Plans at 2025 Conference

If you are holding or watching Twist Bioscience (TWST), the company’s recent spotlight at the Baird Global Healthcare Conference 2025 might have you paying a little closer attention. Management underscored how they have pushed gross margins beyond 50% and set their sights on adjusted EBITDA breakeven by fiscal 2026, a target that signals steady operational progress. In addition to these milestones, Twist’s leadership shared their roadmap for capturing more biopharma business and deepening ties with emerging sequencing customers, all while emphasizing both innovation and cost control in a challenging funding climate.

Twist Bioscience shares have had a turbulent year, sliding nearly 39% over the past twelve months and still searching for a firmer footing after dropping 22% in the past three months. While the stock briefly caught a wave of enthusiasm on recent improvements, long-term investors have felt the pain, given the more than 62% loss over five years. The company’s annual revenue rose by 15%, but red ink persists, even as net income losses narrowed. This mixed picture has helped fuel debate around whether the stock’s momentum could finally turn the corner.

With the market beginning to notice operational gains but past returns still in the red, there are questions around whether Twist Bioscience trades at a discount that leaves room for upside, or if the recent optimism is already factored into today’s price.

Most Popular Narrative: 34% Undervalued

According to the most widely followed view, Twist Bioscience is trading well below its perceived fair value, suggesting analysts see significant upside potential if key company targets play out over the coming years.

Continuous product innovation, including new gene fragment offerings and anticipated upcoming product launches, reflects strategic reinvestment into R&D and manufacturing infrastructure, supporting scalability and improved gross margins over the medium to long term.

Want to know why analysts believe the current share price offers big upside? There is a bold vision for growth driven by aggressive expansion plans and a set of financial projections that could surprise even the most seasoned observers. What is the secret behind the bullish target, and which future assumptions might unlock value? Do not miss what is fueling the narrative’s higher price estimate.

Result: Fair Value of $42.14 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, persistent losses and heavy customer concentration could quickly undermine optimism if key customers pull back or if margin improvements fail to hold.

Find out about the key risks to this Twist Bioscience narrative.

Another View: Discounted Cash Flow Perspective

While the market often focuses on share price compared to sales, our SWS DCF model currently cannot provide a fair value because of limited data. Does this mean future upside is more difficult to determine than some believe?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Twist Bioscience for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own Twist Bioscience Narrative

If you want to take a different view or dig deeper into the numbers, you can easily craft your own story in just a few minutes. Do it your way.

A great starting point for your Twist Bioscience research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.

Looking for more investment ideas?

Step up your investment game by checking out other stocks that could transform your portfolio. You will not want to overlook these fresh opportunities available now on Simply Wall St:

• Uncover companies shaking up artificial intelligence by tapping into AI penny stocks, fueling tomorrow’s digital breakthroughs.
• Secure streams of potential income when you check out dividend stocks with yields > 3%, which offer attractive yields for long-term growth.
• Get ahead of market trends by seeking out quantum computing stocks, leading advances in quantum innovation and next-gen computing.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com